Müslüm ŞAHİN, Aynur Eren TOPKAYA, Mahmut AKYILDIZ, Fehime Benli AKSUNGAR, Ahmet SEKBAN

Plasma BNP and homocysteine levels in patients with or without congestive heart failure

Amaç: Konjestif kalp yetersizliğini gösteren bir parametre olarak kabul edilen BNP (B-tipi natriüretik peptid) ile plazma homosistein düzeyi arasındaki ilişki araştırıldı. Çalışma planı: Çalışmaya, konjestif kalp yetersizliği olan yedi hasta (3 kadın, 4 erkek) ile geçirilmiş miyokard infarktüsü ve konjestif kalp yetersizliği öyküsü olmayan 36 hasta (17 kadın, 19 erkek) alındı. Tüm hastalarda plazma BNP ve homosistein düzeyleri ölçüldü ve transtorasik ekokardiyografi yapıldı.Bulgular: On dokuz hastanın (%44) plazma BNP değerleri 15 pg/ml’den düşük bulundu, bu hastaların plazma homosistein düzeyleri 7.91 mol/l’den düşüktü. Yirmi dört hastanın (%55) plazma BNP değerleri ise 68.4 pg/ml’den yüksek bulundu, bu hastaların en düşük plazma homosistein değeri 8.84 mol/l idi. Korelasyon analizinde BNP ve homosistein düzeyleri arasında pozitif ilişki saptandı (r=0.92, p

Konjestif kalp yetersizliği olan ve olmayan hastalarda plazma BNP ve homosistein düzeyleri

Background: We investigated the relationship between brain natriuretic peptide (BNP), a marker for congestive heart failure, and plasma homocysteine levels. Methods: The study included seven patients (3 females, 4 males) with congestive heart failure and 36 patients (17 females, 19 males) without a history of previous myocardial infarction or congestive heart failure. Plasma BNP and homocysteine levels were measured. All the patients were assessed by transthoracic echocardiography.Results: In 19 patients (44%) plasma BNP and homocysteine levels were lower than 15 pg/ml and 7.91 mol/l, respectively, whereas in 24 patients, the corresponding levels were higher than 68.4 pg/ml and 8.84 mol/l. There was a significant positive correlation between plasma BNP and homocysteine levels (r=0.92, p

PDF

___

1) Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, et al. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10(5 Suppl 3):1-30.
2) Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39:571-88.
3) Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-98.
4) Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-807.
5) Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
6) Vasan RS, Beiser A, D’Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003;289:1251-7.
7) Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002;283:H2567-74.
8) Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002;15(2 Pt 1):157-63.
9) Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D’Agostino RB, Jacques PF, et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 2004;25:523-30.
10) McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
11) Rasouli ML, Nasir K, Blumenthal RS, Park R, Aziz DC, Budoff MJ. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis 2005;181:159-65.
12) Maisel A. B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. J Card Fail 2001; 7:183-93.
13) Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.
14) Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19:217-46.
15) Gerdes VE, Hovinga HA, ten Cate H, Macgillavry MR, Leijte A, Reitsma PH, et al. Homocysteine and markers of coagulation and endothelial cell activation. J Thromb Haemost 2004;2:445-51.
16) Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003;285:H679-86.
17) Frank JS, Langer GA. The myocardial interstitium: its structure and its role in ionic exchange. J Cell Biol 1974;60:586- 601.
18) Janicki JS, Brower GL. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Card Fail 2002;8(6 Suppl):S319-25.
19) Zak R. Cell proliferation during cardiac growth. Am J Cardiol 1973;31:211-9.
20) Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-81.
21) Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, Parker JL. Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Mol Cell Biochem 1998;181:107-16.
22) Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.
23) Upchurch GR, Welch GN, Freedman JE, Loscalzo J. Homocysteine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated cell injury. Circulation 1995;92:1-28.
24) Magliano DJ, Liew D, Ashton EL, Sundararajan V, McNeil JJ. Novel biomedical risk markers for cardiovascular disease. J Cardiovasc Risk 2003;10:41-55.